@misc{indiciae1522c5ad7f7d,
  title = {The human-specific RPGR isoform RPGRs14/15 and the clinically approved Rho/ROCK inhibitor Ripasudil represent therapeutic options to address RPGR-associated defects.},
  author = {Usman, M. and Atigbire, P. and Kastrati, D. and Brinkhoff, J. M. and Kluth, C. and Marticke, J. and Jueschke, C. and Neidhardt, J.},
  year = {2025},
  doi = {10.1101/2025.05.09.653106},
  url = {https://www.biorxiv.org/content/10.1101/2025.05.09.653106v1},
  note = {Source identifier: 10.1101/2025.05.09.653106}
}